NCT01616277View on ClinicalTrials.gov

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
BIOLOGICAL

PF-06252616

1.0 milligram per kilogram of PF-06252616, IV infusion, single dose

DRUG

Placebo

Placebo for PF-06252616, IV infusion, single dose

BIOLOGICAL

PF-06252616

3.0 milligram per kilogram of PF-06252616, IV infusion, single dose

DRUG

Placebo

Placebo for PF-06252616, IV infusion, single dose

BIOLOGICAL

PF-06252161

10.0 milligram per kilogram of PF-06252616, IV infusion, single dose

DRUG

Placebo

Placebo for PF-06252616, IV infusion, single dose

BIOLOGICAL

PF-06252616

3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose

DRUG

Placebo

Placebo for PF-06252616, Subcutaneous injection, single dose

BIOLOGICAL

PF-06252616

10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose

DRUG

Placebo

Placebo for PF-06252616, IV infusion, repeat dose

BIOLOGICAL

PF-06252616

20.0 milligram per kilogram of PF-06252616, IV infusion, single dose

DRUG

Placebo

Placebo for PF-06252616, IV infusion, single dose

BIOLOGICAL

PF-06252616

40.0 milligram per kilogram of PF-06252616, IV infusion, single dose

DRUG

Placebo

Placebo for PF-06252616, IV infusion, single dose

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01616277 - A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects | Biotech Hunter | Biotech Hunter